

# SEQUENCE LISTING

<110> Novartis AG

<120> Formulation of IL-1b antibodies

<130> 53159

<160> 4

<170> PatentIn version 3.3

<210> 1

<211> 117

<212> PRT

<213> Human

<400> 1

Met Glu Phe Gly Leu Ser Trp Val Phe Leu Val Ala Leu Leu Arg Gly  
1 5 10 15

Val Gln Cys Gln Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln  
20 25 30

Pro Gly Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe  
35 40 45

Ser Val Tyr Gly Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu  
50 55 60

Glu Trp Val Ala Ile Ile Trp Tyr Asp Gly Asp Asn Gln Tyr Tyr Ala  
65 70 75 80

Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn  
85 90 95

Thr Leu Tyr Leu Thr Gly Pro Phe Asp Tyr Trp Gly Gln Gly Thr Leu  
100 105 110

Val Thr Val Ser Ser  
115

<210> 2

<211> 126

<212> PRT

<213> Human

<400> 2

Met Leu Pro Ser Gln Leu Ile Gly Phe Leu Leu Leu Trp Val Pro Ala  
1 5 10 15

Ser Arg Gly Glu Ile Val Leu Thr Gln Ser Pro Asp Phe Gln Ser Val

20

25

30

Thr Pro Lys Glu Lys Val Thr Ile Thr Cys Arg Ala Ser Gln Ser Ile  
 35 40 45

Gly Ser Ser Leu His Trp Tyr Gln Gln Lys Pro Asp Gln Ser Pro Lys  
 50 55 60

Leu Leu Ile Lys Tyr Ala Ser Gln Ser Phe Ser Gly Val Pro Ser Arg  
 65 70 75 80

Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Asn Ser  
 85 90 95

Leu Glu Ala Glu Asp Ala Ala Ala Tyr Tyr Cys His Gln Ser Ser Ser  
 100 105 110

Leu Pro Phe Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys  
 115 120 125

<210> 3  
 <211> 410  
 <212> DNA  
 <213> human

<400> 3  
 atggagtttg ggctgagctg ggttttcctc gttgctcttt taagaggtgt ccagtgtcag 60  
 gtgcagctgg tggagtctgg gggaggcgtg gtccagcctg ggaggtccct gagactctcc 120  
 tgtgcagcgt ctggattcac cttcagtgtt tatggcatga actgggtccg ccaggctcca 180  
 ggcaaggggc tggagtgggt ggcaattatt tggatatgat gagataatca atactatgca 240  
 gactccgtga agggccgatt caccatctcc agagacaatt ccaagaacac gctgtatctg 300  
 caaatgaacg gcctgagagc cgaggacacg gctgtgtatt attgtgcgag agatcttagg 360  
 actgggcctt ttgactactg gggccaggga accctgggtca ccgtctcctc 410

<210> 4  
 <211> 378  
 <212> DNA  
 <213> human

<400> 4  
 atgttgccat cacaactcat tgggtttctg ctgctctggg ttccagcctc caggggtgaa 60  
 attgtgctga ctcagtctcc agactttcag tctgtgactc caaaggagaa agtcaccatc 120  
 acctgccggg ccagtcagag cattggtagt agcttacact ggtaccagca gaaaccagat 180  
 cagtctccaa agctcctcat caagtatgct tccagtcct tctcaggggt cccctcgagg 240  
 ttcagtggca gtggatctgg gacagatttc accctcacca tcaatagcct ggaagctgaa 300

gatgctgcag cgtattactg tcatcagagt agtagtttac cattcacttt cggccctggg 360

accaaagtgg atatcaaa 378